There are 2789 resources available
173P - What to expect from NCCN BRCA testing criteria: A retrospective cohort analysis
Presenter: Burak Aktas
Session: ePoster Display
287P - Burden of illness of HER2+ in metastatic breast cancer (MBC) patients: A systematic literature review (SLR)
Presenter: Gerard Vondeling
Session: ePoster Display
175P - Prosigna test for early breast cancer patients in real-life
Presenter: Delphine Hequet
Session: ePoster Display
289P - A retrospective population-based observational study in metastatic HER2-positive breast cancer patients in Denmark previously treated with T-DM1
Presenter: Asbjørn Due
Session: ePoster Display
177P - Pathogenicity reclassification of unknown significance variants related to early-onset breast cancer women of mongoloid origin
Presenter: Polina Gervas
Session: ePoster Display
178P - Age-related mutational landscape of luminal breast cancers
Presenter: Nawale Hajjaji
Session: ePoster Display
179P - Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin for early triple-negative breast cancer: A single-arm, open-label, phase II study
Presenter: Chengzheng Wang
Session: ePoster Display
293P - Exploring the interplay between tumor burden and liquid biopsy longitudinal evaluation in hormone receptor-positive, HER2-negative metastatic breast cancer (MBC)
Presenter: Roberta Mazzeo
Session: ePoster Display
294P - Cell-free DNA (cfDNA) workflow for the risk definition of dose-limiting and recurrent neutropenia in patients treated with first-line endocrine therapy (ET) and cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) for metastatic breast cancer (MBC)
Presenter: Lorenza Palmero
Session: ePoster Display